Corlift (Vericiguat INN) 10 mg
£0.00
Indications
Pharmacology
Dosage & Administration
Recommended Starting Dose: The recommended starting dose of Vericiguat is 2.5 mg orally once daily with food. Double the dose of Vericiguat approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablet, Vericiguat may be crushed and mixed with water immediately before administration or as directed by physician.
Geriatric Patients: No dosage adjustment of Vericiguat is required in geriatric patients. No overall differences in safety or efficacy of Vericiguat were observed between patients aged 65 years and older compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Hepatic Impairment: No dosage adjustment of Vericiguat is recommended in patients with mild or moderate hepatic impairment.
Renal Impairment: No dosage adjustment of Vericiguat is recommended in patients with estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m2 who are not on dialysis. Vericiguat has not been studied in patients with eGFR <15 mL/min/1.73m2 at treatment initiation or on dialysis.
Use in Children & Adolescents: Safety and effectiveness of Vericiguat have not been established in pediatric patients.
Interaction
Other Soluble Guanylate Cyclase Stimulators: Corlift is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
PDE-5 Inhibitors: Concomitant use of Corlift with PDE-5 inhibitors is not recommended because of the potential for hypotension.
With food & others: Corlift should be taken with food. The absolute bioavailability of Corlift is 93% when taken with food.
Contraindications
Side Effects
Pregnancy & Lactation
Pregnancy: Vericiguat is contraindicated in pregnancy because it may cause fetal harm. Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment.
Nursing Mothers: There are no data on the presence of Vericiguat in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from Vericiguat, women should be advised not to breastfeed during treatment with Vericiguat.
Precautions & Warnings
Overdose Effects
Therapeutic Class
Storage Conditions
Generic Name: | Vericiguat INN |
---|---|
Theraputic Category: | SGC Stimulator |
Pack Size: | 3×10's, 2×10's, 1×10's |
You must be logged in to post a review.
Reviews
There are no reviews yet.